291 related articles for article (PubMed ID: 28535455)
1. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.
Eibl JK; Gauthier G; Pellegrini D; Daiter J; Varenbut M; Hogenbirk JC; Marsh DC
Drug Alcohol Depend; 2017 Jul; 176():133-138. PubMed ID: 28535455
[TBL] [Abstract][Full Text] [Related]
2. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.
Gauthier G; Eibl JK; Marsh DC
Drug Alcohol Depend; 2018 Oct; 191():1-5. PubMed ID: 30064001
[TBL] [Abstract][Full Text] [Related]
3. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
Crowley D; Delargy I
Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
5. Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
Spithoff S; Meaney C; Urbanoski K; Harrington K; Que B; Kahan M; Leece P; Shehadeh V; Sullivan F
Can Fam Physician; 2019 Oct; 65(10):e443-e452. PubMed ID: 31604755
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada.
Eibl JK; Gomes T; Martins D; Camacho X; Juurlink DN; Mamdani MM; Dhalla IA; Marsh DC
J Addict Med; 2015; 9(6):440-6. PubMed ID: 26484843
[TBL] [Abstract][Full Text] [Related]
7. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin KA; Eibl JK; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Harm Reduct J; 2020 Jul; 17(1):51. PubMed ID: 32703310
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health Data.
Morin KA; Parrotta MD; Eibl JK; Marsh DC
Eur Addict Res; 2021; 27(4):268-276. PubMed ID: 33706309
[TBL] [Abstract][Full Text] [Related]
9. Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.
Tahsin F; Morin KA; Vojtesek F; Marsh DC
BMC Health Serv Res; 2022 Apr; 22(1):490. PubMed ID: 35413980
[TBL] [Abstract][Full Text] [Related]
10. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine.
Weintraub E; Greenblatt AD; Chang J; Himelhoch S; Welsh C
Am J Addict; 2018 Dec; 27(8):612-617. PubMed ID: 30265425
[TBL] [Abstract][Full Text] [Related]
11. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
12. Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.
Morin KA; Tatangelo M; Marsh D
BMJ Open; 2024 Feb; 14(2):e080790. PubMed ID: 38401902
[TBL] [Abstract][Full Text] [Related]
13. Quality of primary care among individuals receiving treatment for opioid use disorder.
Spithoff S; Kiran T; Khuu W; Kahan M; Guan Q; Tadrous M; Leece P; Martins D; Gomes T
Can Fam Physician; 2019 May; 65(5):343-351. PubMed ID: 31088874
[TBL] [Abstract][Full Text] [Related]
14. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
15. Co-Constructing a Community-Based Telemedicine Program for People With Opioid Use Disorder During the COVID-19 Pandemic: Lessons Learned and Implications for Future Service Delivery.
Høj SB; de Montigny C; Chougar S; Léandre R; Beauchemin-Nadeau MÈ; Boyer-Legault G; Goyette A; Lamont SK; Bruneau J
JMIR Public Health Surveill; 2023 Jul; 9():e39236. PubMed ID: 37494097
[TBL] [Abstract][Full Text] [Related]
16. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
[TBL] [Abstract][Full Text] [Related]
17. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
[TBL] [Abstract][Full Text] [Related]
18. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
[TBL] [Abstract][Full Text] [Related]
19. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
Van Hout MC; Crowley D; McBride A; Delargy I
BMC Fam Pract; 2018 Jun; 19(1):103. PubMed ID: 29960593
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
Marsden J; Stillwell G; Hellier J; Brown AM; Byford S; Kelleher M; Kelly J; Murphy C; Shearer J; Mitcheson L
Contemp Clin Trials; 2017 Feb; 53():36-43. PubMed ID: 27940188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
